ADPT — Adaptive Biotechnologies Corpor
Is ADPT overbought or oversold? Here is the current MarketMoodz read.
Adaptive Biotechnologies Corpor (ADPT) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $28.49. The rating moved from Overbought to Neutral on November 12, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$28.49
- Last changeMoved from Overbought to Neutral on November 12, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
AI analysis
Adaptive Biotechnologies combines a differentiated immune‑sequencing platform with a nascent diagnostics commercial franchise that offers upside if payer adoption and partner collaborations scale. Near‑term momentum is likely to be driven by incremental commercial execution, partnership milestones and any evidence of improving reimbursement. Key constraints are execution risk, reimbursement uncertainty, competition from larger players and potential cash‑runway pressures; absent a clear new catalyst, expect consolidation around current levels with modest upside if operational targets are met.
Key factors
- Proprietary immune‑sequencing platform and diagnostic product portfolio provide differentiated technology and recurring revenue potential
- Existing commercial traction in specialized diagnostics (minimal residual disease / immunosequencing use cases) supports revenue base and clinical credibility
- Partnerships and collaborations with larger biopharma firms can accelerate development and provide non‑dilutive revenue or milestone upside
- Market environment showing selective support for growth and biotech exposures, which could stabilize share price in the near term
- Limited near‑term macro/regulatory shocks in the market reduce immediate downside from risk‑off flows
- Execution sensitivity: revenue growth depends on payer adoption, sales execution, and successful translation of R&D into commercial products
Risks
- Reimbursement and payer pushback that could slow adoption of diagnostics and pressure revenue realization
- Clinical or regulatory setbacks for diagnostic indications or partnerships that reduce future revenue visibility
- Competition from larger diagnostics, genomics and pharma players with greater commercial reach and pricing power
- Cash‑burn and financing risk if growth needs exceed existing capital, potentially leading to dilution
- Concentration risk from a small number of product lines or large customers/partners
- Broader biotech sector volatility and rotation away from growth stocks could amplify share price downside
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ADPT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.